(secondQuint)Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa.

 The primary objective of this study is to assess the efficacy of subcutaneously administered efalizumab in the treatment of refractory, severe hydradenitis suppurativa.

 The secondary objectives of this study are to assess the ability to re-establish disease control after discontinuation of drug and allowance for relapse of disease, as well as to assess the safety of subcutaneously administered efalizumab in the treatment of refractory, severe hydradenitis suppurativa.

.

 Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa@highlight

The purpose of this study is to determine the effectiveness and safety of efalizumab in treating hydradenitis suppurativa, and to evaluate the duration of the benefit seen in people who respond to treatment with efalizumab, after the medication is stopped.

